Pembrolizumab (Keytruda®) in combination with lenvatinib (Lenvima®) for endometrial carcinoma. HTA ID: 22006

Assessment Status NCPE Assessment Process Complete
HTA ID 22006
Drug Pembrolizumab
Brand Keytruda®
Indication In combination with lenvatinib (Lenvima®) is indicated for the treatment of advanced or recurrent endometrial carcinoma in adults who have disease progression on or following prior treatment with a platinum-containing therapy in any setting, and who are not candidates for curative surgery or radiation.
Assessment Process
Rapid review commissioned 07/02/2022
Rapid review completed 04/03/2022
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab in combination with lenvatinib compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 01/04/2022
Pre-submission consultation with Applicant 09/05/2022
Full submission received from Applicant 21/02/2023
Preliminary review sent to Applicant 03/08/2023
NCPE assessment re-commenced 05/09/2023
Follow-up to preliminary review sent to Applicant 19/09/2023
NCPE assessment re-commenced 06/11/2023
Factual accuracy sent to Applicant 01/12/2023
NCPE assessment re-commenced 11/12/2023
NCPE assessment completed 18/12/2023
NCPE assessment outcome The NCPE recommends that pembrolizumab, in combination with lenvatinib, not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*.

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.